Our top pick for
Metacrine, Inc. is a biotechnology business based in the US. Metacrine shares (MTCR) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$10.79|
|52-week range||USD$9.06 - USD$16.19|
|50-day moving average||USD$10.3304|
|200-day moving average||USD$10.3304|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||8.77%|
|1 month (2020-10-23)||18.57%|
|3 months (2020-08-21)||N/A|
|6 months (2020-05-21)||N/A|
|1 year (2019-11-21)||N/A|
|2 years (2018-11-21)||N/A|
|3 years (2017-11-21)||N/A|
|5 years (2015-11-21)||N/A|
|Revenue TTM||USD$2.2 million|
|Gross profit TTM||USD$-25,973,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$253.8 million|
TTM: trailing 12 months
There are currently 398,579 Metacrine shares held short by investors – that's known as Metacrine's "short interest". This figure is up from 0 last month.
There are a few different ways that this level of interest in shorting Metacrine shares can be evaluated.
Metacrine's "short interest ratio" (SIR) is the quantity of Metacrine shares currently shorted divided by the average quantity of Metacrine shares traded daily (recently around 428579.56989247). Metacrine's SIR currently stands at 0.93. In other words for every 100,000 Metacrine shares traded daily on the market, roughly 930 shares are currently held short.
To gain some more context, you can compare Metacrine's short interest ratio against those of similar companies.
However Metacrine's short interest can also be evaluated against the total number of Metacrine shares, or, against the total number of tradable Metacrine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Metacrine's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Metacrine shares in existence, roughly 20 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable Metacrine shares, roughly 22 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Metacrine.
Find out more about how you can short Metacrine stock.
We're not expecting Metacrine to pay a dividend over the next 12 months.
You may also wish to consider:
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities related to fibroblast growth factor 1. Metacrine, Inc. was founded in 2014 and is headquartered in San Diego, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.